Novo Nordisk's Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed

A 30-day supply of the first oral GLP-1 agonist will cost $772.43 in the US, similar to the injectable version but steeper than oral diabetes medicines. Deep discounts may be needed to secure market access.

Scales_140867215_1200.jpg
Rybelsus to be priced at parity to injectable GLP-1s • Source: Shutterstock

More from New Products

More from Scrip